DSDaisuke Shishikura

Daisuke Shishikura

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Daisuke Shishikura has a total of 27 co-authors. Here are the top co-authors by number of shared publications:

  • Hideaki Morita

    Department of Cardiology, Osaka Medical and Pharmaceutical University Hospital, Osaka, Japan

    7 shared publications
  • Yumiko Kanzaki

    Department of Cardiology, Osaka Medical and Pharmaceutical University Hospital, Osaka, Japan

    7 shared publications
  • Hirofumi Kusumoto

    Department of Cardiology, Osaka Medical and Pharmaceutical University

    5 shared publications
  • Mariko Harada-Shiba

    Department of Cardiology, Osaka Medical and Pharmaceutical University Hospital, Osaka, Japan

    5 shared publications
  • Masahito Michikura

    Department of Cardiology, Osaka Medical and Pharmaceutical University

    5 shared publications
  • Tomohiro Fujisaka

    Department of Cardiology, Osaka Medical and Pharmaceutical University Hospital, Osaka, Japan

    5 shared publications

Latest Publications

  • Physiological assessment of coronary microvascular dysfunction and short-term outcomes in severely calcified coronary lesions: a comparison between rotational atherectomy and intravascular lithotripsy

    by Hirofumi Kusumoto, Daisuke Shishikura, Kenta Sakaguchi, Simpei Fujioka, Yohei Yamauchi, Tomohiro Fujisaka, Yumiko Kanzaki, Mariko Harada-Shiba, Hideaki Morita

    Coronary artery calcification (CAC), one of the greatest challenges of percutaneous coronary intervention (PCI), is associated with a poor prognosis. We therefore conducted a wire-derived physiological evaluation to investigate the influence of CAC modification using intravascular lithotripsy (IVL) and rotational atherectomy (RA) on the coronary circulation. A total of 154 patients with CAC requiring IVL or RA were enrolled in this single-center, retrospective study. Physiological assessments, particularly Index of microcirculatory resistance (IMR), coronary flow reserve (CFR), resistive reserve ratio (RRR), and microvascular resistance reserve (MRR) were performed using a temperature-sensor guidewire (Pressure Wire X, Abbott) pre- and post-PCI and compared between IVL and RA. Procedural and 30-day clinical outcomes were also evaluated. Seventy patients were treated with IVL and 84 with RA. IVL and RA demonstrated comparable lumen expansion. In the physiological assessments, RA significantly increased post-IMR compared to IVL (17.0 [10.5–32.8] vs.12.0 [9.00–19.0], p = 0.03), which was correlated with severity of periprocedural myocardial Infarction (MI) (Spearman’s ρ = 0.40, p = 0.01). Post-CFR, post-RRR, and post-MRR were significantly higher with IVL than RA (3.20 [2.00—4.60] vs. 1.55 [1.20—2.10], p < 0.01, 2.90 [2.10—4.70] vs. 1.60 [1.20–2.42], p < 0.01, 2.77 [2.05—4.54] vs. 1.50 [1.20—2.37], p < 0.01, respectively). Use of RA was associated with post-PCI coronary microvascular dysfunction (OR: 4.77, 95% CI:1.51–17.56). Slow flow phenomenon and procedure-related MI were more frequently observed with RA than IVL (19.1% vs. 4.3%, p < 0.01, 35.7% vs. 7.1%, p < 0.01, respectively). In patients with severely calcified coronary lesions, IVL and RA achieved comparable epicardial results, whereas IVL was associated with more favorable post-procedural microvascular physiological indices than RA. Although RA was associated with increased procedural MI, this was not accompanied by a significant difference in short-term major adverse events. Further studies with large populations and long-term follow-up are warranted to determine the clinical significance of these physiological differences. Graphical Abstract

  • Open Access

    Comparison of Clinical Characterization and Therapeutic Strategies between Homozygous Familial Hypercholesterolemia and Heterozygous Familial Hypercholesterolemia

    by Daisuke Shishikura, Mariko Harada-Shiba, Masahito Michikura, Kenta Sakaguchi, Hirofumi Kusumoto, Shimpei Fujioka, Tomohiro Fujisaka, Yumiko Kanzaki, Hideaki Morita

    Aims: Homozygous Familial hypercholesterolemia (HoFH) is a rare genetic disease characterized by very high levels of low-density lipoprotein cholesterol (LDL-C). Owing to LDL receptor activity being completely or nearly all lost in HoFH, LDL-C levels greatly exceed normal levels, and are even higher than in heterozygous (HeFH), which can cause fatal cardiovascular disease even in infancy. The current study updates differences in clinical characterization, therapeutic strategies and cardiovascular outcomes between HoFH and HeFH.Methods: A total of 157 patients who were genetically or clinically diagnosed with FH (HoFH: 15, HeFH: 142) were retrospectively analyzed. Clinical characteristics, lipid profiles and atherosclerotic prognosis were evaluated between HoFH and HeFH patients.Results: Age and sex were similar between the two groups. Untreated LDL-C in HoFH was about double that in HeFH (498.4±164.3 vs. 232.0±60.5 mg/dL, p<0.001), while on-treatment LDL-C with lipid lowering therapies did not differ significantly (83.8±59.1 vs. 127.1±59.6 mg/dL, p = 0.15). There was wide diversity in lipid lowering therapies between the two groups and a significantly higher prevalence of coronary artery and valvular disease in HoFH. Consequently, HoFH patients were more likely to receive percutaneous and surgical interventions at a younger age compared to HeFH patients.Conclusions: The findings of this observational study show the clinical relevance of FH. Although both HeFH and HoFH are inherited disorders of lipoprotein metabolism, HoFH should be treated with a different, stricter therapeutic strategy to prevent premature ASCVD.


  • Open Access

    Discordance in Achilles Tendon Assessment between Radiography and Ultrasonography due to Torsion

    by Kenta Sakaguchi, Shimpei Fujioka, Daisuke Shishikura, Masahito Michikura, Hirofumi Kusumoto, Yumiko Kanzaki, Mariko Harada-Shiba, Hideaki Morita

    Aim: Tendon xanthomas are part of the clinical triad of diagnostic criteria for familial hypercholesterolemia (FH) in Japan. The Achilles tendon generally has a twisted structure, and we investigated the impact of torsion on Achilles tendon thickness (ATT) assessment.Methods: In this single-center retrospective study, 61 acute coronary syndrome (ACS) patients who underwent ATT assessment using radiography (ATT-Xp) and ultrasonography (ATT-US) were analyzed. Ultrasonographic ATT assessment used two axes - antero-posterior axis (ATT-US (AP)) and corrected axis according to Achilles tendon torsion (ATT-US (correct)) - and the torsion angle was measured. The association of torsion with each ATT assessment was investigated.Results: The torsion angle of the Achilles tendon varied widely. Both ATT-US (AP) and ATT-US (correct) were significantly correlated with ATT-Xp, although the correlation between ATT-Xp and ATT-US (correct) was modest compared to the correlation with ATT-US (AP) (ATT-US (AP)-Right: r= 0.91, p<0.001, Left: r= 0.91, p<0.001; ATT-US (correct)-Right: r = 0.82, p<0.001, Left: r = 0.76, p<0.001, respectively). Torsion angle was well correlated with the differences in ATT between ATT-Xp and ATT-US (correct) (Right: r= 0.62, p<0.001, Left: r= 0.66, p<0.001). There were no independent factors associated with Achilles tendon torsion.Conclusion: This is the first study to quantitatively evaluate the three-dimensional twisted structure of the Achilles tendon and demonstrate that Achilles tendon torsion is associated with the difference between ATT-Xp and ATT-US (correct). Torsion of the Achilles tendon should be considered in Achilles tendon assessment, particularly radiographical assessment.


  • Haemodynamic and blood viscosity profiles of culprit vs. non-culprit coronary vessels: Insights from NIRS-IVUS and CFD analysis

    by Eric K.W. Poon, Daisuke Shishikura, Jeremy D. Silver, Lucas Hatzikostas, Philip Macanovic, Jouke Dijkstra, Patrick W. Serruys, Hideaki Morita, Peter Barlis


  • Open Access

    Safety and clinical outcomes of micro-axial intravascular flow pump compared to intra-aortic balloon pump in cardiogenic shock

    by Mana Makino, Daisuke Shishikura, Hirofumi Kusumoto, Yohei Yamauchi, Kazushi Sakane, Tomohiro Fujisaka, Ryosuke Zushi, Yumiko Kanzaki, Masaaki Hoshiga, Hideaki Morita

    Background: The micro-axial intravascular flow pump (mAFP) may potentially improve the prognosis of cardiogenic shock (CS). Despite its advanced hemodynamic profile, efficacy remains undetermined. Safety and mid-term outcomes were compared between the mAFP and intra-aortic balloon pump (IABP). Methods: This single-center, cross-sectional study retrospectively evaluated 205 consecutive patients treated using the IABP or mAFP at Osaka Medical and Pharmaceutical University from January 2017 to June 2023. After exclusion of those with CS who were treated with only extracorporeal membrane oxygenation (ECMO), patients who required IABP or mAFP were enrolled in the current study. The primary outcome was 180-day mortality. Secondary outcomes were major [major bleeding (Bleeding Academic Research Consortium criteria 3–5), limb ischemia and stroke] and other complications (hemolysis, thrombocytopenia, acute kidney impairment and requirement of renal replacement therapy). Those outcomes were compared between IABP and mAFP. Results: Of all patients, 62 (30.2%) received the mAFP and 143 (69.8%) the IABP. There were no significant differences in 180-day mortality between the devices (P=0.86). Further investigation according to the Society for Cardiovascular Angiography and Intervention (SCAI) shock stage classification demonstrated that the mortality rate for SCAI C was significantly lower in the mAFP group (P=0.02), while mortality was not significantly different for SCAI D/E (P=0.71). The major and other complications were more frequent in the mAFP group (61.3% vs. 46.0%, P=0.02 and 90.3% vs. 68.8%, Pvs. IABP) (HR: 5.27, 95% CI: 1.71–16.30), age ≥75 years (HR: 2.80, 95% CI: 1.28–6.11) and ECMO use (HR: 8.34, 95% CI: 2.33–29.9) were independent predictors of other complications. Conclusions: Classical CS attained benefit from the mAFP, whereas it is still challenging for patients with severe CS, particularly OHCPA and requirement for ECMO. The use of mAFP was associated with more complications and its true impact on clinical outcomes remains to be determined.

  • Open Access

    Association of Achilles Tendon Thickness with Severity of Coronary Artery Disease in Non -Familial Hypercholesterolemia

    by Shimpei Fujioka, Daisuke Shishikura, Kenta Sakaguchi, Hirofumi Kusumoto, Masahito Michikura, Yumiko Kanzaki, Mariko Harada-Shiba, Hideaki Morita

    Aim: Achilles tendon xanthomas are a characteristic feature of familial hypercholesterolemia (FH). Achilles tendon thickness (ATT) has been associated with the severity of coronary artery disease (CAD) in FH. However, its relevance in non-FH remains unclear. Therefore, we assessed the relationship between ATT and CAD severity in patients with acute coronary syndrome (ACS) without FH.Methods: A total of 194 patients (mean age: 69.1±11.9 years) with ACS without FH were retrospectively investigated and divided into two groups: single-vessel disease (SVD) or multivessel disease (MVD). ATT was measured using ultrasonography (US-ATT) and radiography (Xp-ATT). The association between ATT and CAD severity was evaluated.Results: Of the total, 107 patients (55.2%) had SVD, and 87 (44.8%) had MVD. Mean US-ATT and Xp-ATT values were 5.0±0.6 mm and 6.4±1.2 mm, respectively. ATT was significantly greater in the MVD group than in the SVD group (US-ATT: 5.2 mm vs. 4.8 mm, p<0.01; Xp-ATT: 6.6 mm vs. 6.1 mm, p = 0.01) and correlated with the SYNTAX score (US-ATT: r = 0.30, p<0.01; Xp-ATT: r = 0.19, p = 0.02). Multivariable analysis identified US-ATT as an independent predictor of MVD (odds ratio: 2.71; 95% confidence interval: 1.46–5.01; p<0.01).Conclusion: In patients with ACS without FH, ATT was significantly associated with CAD severity. This suggests that ATT, particularly US-ATT, may serve as a practical, non-invasive marker for cardiovascular risk stratification.


  • Open Access

    Clinical Impact of Lipoprotein (a) and Cumulative Low-Density Lipoprotein Cholesterol Exposure on Coronary Artery Disease in Patients with Heterozygous Familial Hypercholesterolemia

    by Daisuke Shishikura, Mariko Harada-Shiba, Masahito Michikura, Shimpei Fujioka, Tomohiro Fujisaka, Hideaki Morita, Yumiko Kanzaki, Masaaki Hoshiga

    Aims: Elevated lipoprotein (a) (Lp[a]), predominantly determined by genetic variability, causes atherosclerotic cardiovascular disease (ASCVD), particularly in patients with familial hypercholesterolemia (FH). We aimed to elucidate the clinical impact of Lp(a) and cumulative exposure to low-density lipoprotein cholesterol (LDL-C) on CAD in patients with FH.Methods: One hundred forty-seven patients clinically diagnosed with heterozygous familial hypercholesterolemia (HeFH) were retrospectively investigated. Patients were divided into 2 groups according to the presence of CAD. Their clinical characteristics and lipid profiles were evaluated.Results: There were no significant differences in untreated LDL-C levels between the 2 groups (p=0.4), whereas the cumulative exposure to LDL-C and Lp(a) concentration were significantly higher in patients with CAD (11956 vs. 8824 mg-year/dL, p<0.01; 40 vs. 14 mg/dL, p<0.001, respectively). A receiver operating characteristic (ROC) curve analysis demonstrated that the cutoff values of Lp(a) and cumulative LDL-C exposure to predict CAD in patients with FH were 28 mg/dL (AUC 0.71) and 10600 mg-year/dL (AUC 0.77), respectively. A multivariate analysis revealed that cumulative LDL-C exposure ≥ 10600 mg-year/dL (p<0.0001) and Lp(a) level ≥ 28 mg/dL (p<0.001) were independent predictors of CAD. Notably, the risk of CAD remarkably increased to 85.7% with smoking, Lp(a) ≥ 28 mg/dL, and cumulative LDL-C exposure ≥ 10600 mg-year/dL (odds ratio: 46.5, 95%CI: 5.3–411.4, p<0.001).Conclusions: This study demonstrated an additive effect of Lp(a) and cumulative LDL-C exposure on CAD in patients with HeFH. Interaction with traditional risk factors, particularly smoking and cumulative LDL-C exposure, enormously enhances the cardiovascular risk in this population.


  • Open Access

    Clinical impact of ≥50% reduction of low density lipoprotein cholesterol following lipid lowering therapy on cardiovascular outcomes in patients with acute coronary syndrome

    by Shimpei Fujioka, Daisuke Shishikura, Hirofumi Kusumoto, Yohei Yamauchi, Kazushi Sakane, Tomohiro Fujisaka, Kensaku Shibata, Hideaki Morita, Yumiko Kanzaki, Masahito Michikura, et al.